December 22, 2016 - An MLO special feature article written by Cynvenio Chief Medical Officer, Dr. Paul Song discussing liquid biopsy as a promising new approach to monitor TNBC patients post-treatment.
August 11, 2016 - Article in Clinical Lab Products (CLP) magazine by Cynvenio Chief Science Officer, Paul Dempsey, PhD, discussing improvements in liquid biopsy techniques and the analysis of rare cancer-derived events present among normal cells or DNA.
June 20, 2016 - An Interview with Paul W. Dempsey, PhD, and Paul Y. Song, MD, of Cynvenio.
May 25, 2016 - Jim Cramer interviews Thermo Fisher Scientific CEO, Marc Casper. In this segment, Casper discusses Cynvenio and LiquidBiopsy.
May 9, 2016 - Article published by Clinical Lab Products discussing the results of Cynvenio's study.
April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.
Dr. Kristi Funk, Angelina Jolie's surgeon and co-founder of the Pink Lotus Breast Center, discusses Cynvenio's new clinical research study for women with triple negative breast cancer (TNBC).
March 15, 2015 - GEN Magazine profiles Cynvenio and the LiquidBiopsy platform. The article identifies that LiquidBiopsy is on the path to mainstream usage, buoyed by the efficacy of molecular data in improving outcomes.
Jan. 26, 2015 - With evidence building that monitoring a tumor's mutational landscape can be done by evaluating circulating tumor DNA or circulating tumor cells, companies are increasingly looking to move into the liquid biopsy market. Over the last month, the larger players in cancer genomics have all announced their intentions to get into the market, as well.
September 15, 2014 - The ASCO Post talked with Dr. Cristofanilli, a member of Cynvenio's clinical advisory board, about the accuracy of liquid biopsies in detecting and analyzing cancer, their potential use as a tool for cancer screening in healthy people, and how they can provide accurate prognostic information in patients with recurrent disease.
Sept. 10, 2014 - In this Clinical Sequencing News article published by GenomeWeb, Paul Dempsey, Ph.D., Cynvenio’s CSO, is interviewed about the company’s research and activities to establish the utility of cell-free DNA relative to, and potentially in combination with CTC analysis. [Premium Subscriber Content]
September 7, 2014 - Jennifer Smith, award winning broadcaster and host of 77WABC Radio's Optimal Wellness hour, interviews Dr. Joe Bosiljevac and Cynvenio's Chief Scientific Officer, Paul Dempsey about the ClearID genomic blood test.
June 17, 2014 - Cynvenio CEO, Andre' de Fusco, and Cynvenio CSO, Paul Dempsey, interviewed on Mad Money with Jim Cramer.